litlas
Log inCreate account

Vered Stearns

Active 1998–2025

115
Papers
20,471
Citations
76
h-index
110
i10-index

Citations

Citations per year for Vered Stearns1948: 1 citations1971: 1 citations1999: 1 citations2000: 1 citations2001: 6 citations2002: 20 citations2003: 50 citations2004: 39 citations2005: 73 citations2006: 85 citations2007: 92 citations2008: 84 citations2009: 87 citations2010: 120 citations2011: 127 citations2012: 137 citations2013: 175 citations2014: 144 citations2015: 246 citations2016: 222 citations2017: 223 citations2018: 205 citations2019: 642 citations2020: 684 citations2021: 703 citations2022: 586 citations2023: 385 citations2024: 620 citations2025: 246 citations2026: 13 citations1949–1970: no citations, so these years are not shown1972–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,376 citing papers, 28.8% of this breakdownChina: 661 citing papers, 8% of this breakdownUnited Kingdom: 499 citing papers, 6% of this breakdownItaly: 468 citing papers, 5.7% of this breakdownGermany: 376 citing papers, 4.6% of this breakdownCanada: 328 citing papers, 4% of this breakdownFrance: 321 citing papers, 3.9% of this breakdownAustralia: 254 citing papers, 3.1% of this breakdownSpain: 227 citing papers, 2.7% of this breakdownSwitzerland: 201 citing papers, 2.4% of this breakdownNetherlands: 193 citing papers, 2.3% of this breakdownJapan: 181 citing papers, 2.2% of this breakdown
0%28.8%Other 26.3%

Institutions

Fields

  • Medicine44.6%
  • Biochemistry, Genetics and Molecular Biology43.5%
  • Pharmacology, Toxicology and Pharmaceutics3.6%
  • Immunology and Microbiology3%
  • Computer Science1.1%
  • Neuroscience0.8%
  • Other3.4%

Topics

  • Breast Cancer Treatment Studies8.1%
  • Estrogen and related hormone effects4.5%
  • Advanced Breast Cancer Therapies3.8%
  • Cancer Genomics and Diagnostics3.8%
  • HER2/EGFR in Cancer Research3.6%
  • Epigenetics and DNA Methylation2.9%
  • Other73.3%

Coauthors

All papers

Open in search
  1. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

    Authors: Fabrice Andre, Nofisat Ismaila, Kimberly H. Allison, William E. Barlow, Deborah E. Collyar, Senthil Damodaran, N. Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M. Kuderer, Anya Litvak, Erica L. Mayer, Lajos Pusztai, Rachel Raab, Antonio C. Wolff, Vered Stearns - Journal of Clinical Oncology 2022 cited by 347

  2. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

    Authors: Harold J. Burstein, Christina Lacchetti, Holly Anderson, Thomas A. Buchholz, Nancy E. Davidson, Karen A. Gelmon, Sharon H. Giordano, Clifford A. Hudis, Alexander J. Solky, Vered Stearns, Eric P. Winer, Jennifer J. Griggs - Journal of Clinical Oncology 2018 cited by 630

  3. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  4. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Authors: Olivia Pagani, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis - Journal of Clinical Oncology 2022 cited by 154

  5. Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Authors: Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, Hope S. Rugo, Lisle M. Nabell, Andres Forero, Vered Stearns, Ashley S. Doane, Michael A. Danso, Mary Ellen Moynahan, Lamia F. Momen, Joseph M. Gonzalez, Arooj Akhtar, Dilip D. Giri, Sujata Patil, Kimberly Feigin, Clifford A. Hudis, Tiffany A. Traina - Clinical Cancer Research 2013 cited by 740

  6. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles E. Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P. Winer, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Anita Giobbie‐Hurder, Karen N. Price, Jürg Bernhard, Weixiu Luo, Karin Ribi, Giuseppe Viale, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis - New England Journal of Medicine 2014 cited by 747

  7. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

    Authors: Roisín M. Connolly, Huili Li, Rachel C. Jankowitz, Zhe Zhang, Michelle A. Rudek, Stacie C. Jeter, Shannon A. Slater, Penny Powers, Antonio C. Wolff, John H. Fetting, Adam Brufsky, Richard Piekarz, Nita Ahuja, Peter W. Laird, Hui Shen, Daniel J. Weisenberger, Leslie Cope, James G. Herman, George Somlo, Agustin A. García, Peter A. Jones, Stephen B. Baylin, Nancy E. Davidson, Cynthia A. Zahnow, Vered Stearns - Clinical Cancer Research 2016 cited by 159

  8. Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

    Authors: Hsing-Chen Tsai, Huili Li, Leander Van Neste, Yi Cai, Carine Robert, Feyruz V. Rassool, James Shin, Kirsten Harbom, Robert M. Beaty, Emmanouil P. Pappou, James Harris, Ray-Whay Chiu Yen, Nita Ahuja, Malcolm V. Brock, Vered Stearns, David Feller‐Kopman, Lonny Yarmus, Yi‐Chun Lin, Alana L. Welm, Jean‐Pierre J. Issa, Il Minn, William Matsui, Yoon-Young Jang, Saul J. Sharkis, Stephen B. Baylin, Cynthia A. Zahnow - Cancer Cell 2012 cited by 647

  9. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

    Authors: Huili Li, Katherine B. Chiappinelli, Angela A. Guzzetta, Hariharan Easwaran, Ray-Whay Chiu Yen, Rajita Vatapalli, Michael J. Topper, Jianjun Luo, Roisín M. Connolly, Nilofer S. Azad, Vered Stearns, Drew M. Pardoll, Nancy E. Davidson, Peter A. Jones, Dennis J. Slamon, Stephen B. Baylin, Cynthia A. Zahnow, Nita Ahuja - Oncotarget 2014 cited by 439

  10. Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors

    Authors: Ahmed Hassoon, Yasmin Baig, Daniel Q. Naiman, David D. Celentano, Dina Lansey, Vered Stearns, Josef Coresh, Jennifer A. Schrack, Seth S. Martin, Hsin-Chieh Yeh, Hadas Zeilberger, Lawrence J. Appel - npj Digital Medicine, npj Digit. Medicine 2021 cited by 59

  11. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

    Authors: Heather A. Parsons, Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G. Abramson, Ayan R. Patel, Justin Cheng, Adam Brufsky, Justin Rhoades, Jeremy Force, Rong Liu, Tiffany A. Traina, Lisa A. Carey, Mothaffar F. Rimawi, Kathy D. Miller, Vered Stearns, Jennifer M. Specht, Carla I. Falkson, Harold J. Burstein, Antonio C. Wolff, Eric P. Winer, Nabihah Tayob, Ian E. Krop, G. Mike Makrigiorgos, Todd R. Golub, Erica L. Mayer, Viktor A. Adalsteinsson - Annals of Oncology 2023 cited by 57

  12. Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment

    Authors: Dimitrios N. Sidiropoulos, Christine I. Rafie, Julie K. Jang, Sofi Castanon, Aaron G. Baugh, Edgar Gonzalez, Brian J. Christmas, Valerie H. Narumi, Emily F. Davis-Marcisak, Gaurav Sharma, Emma Bigelow, Ajay Vaghasia, Anuj Gupta, Alyza Skaist, Michael Considine, Sarah J. Wheelan, Sathish Kumar Ganesan, Min Yu, Srinivasan Yegnasubramanian, Vered Stearns, Roisin M. Connolly, Daria A. Gaykalova, Luciane T. Kagohara, Elizabeth M. Jaffee, Elana J. Fertig, Evanthia T. Roussos Torres - Cancer Immunology Research 2022 cited by 62

  13. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

    Authors: Evanthia T. Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A. Tandurella, James M. Leatherman, Christine I. Rafie, Chenguang Wang, Adam Brufsky, Patricia LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O’Connor, Sarah M. Shin, Alexei Hernandez, Elizabeth L. Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A. Rudek, Qingfeng Zhu, Robert A. Anders, Ashley Cimino‐Mathews, Elana J. Fertig, Elizabeth M. Jaffee, Vered Stearns, Roisín M. Connolly - Nature Cancer 2024 cited by 47

  14. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

    Authors: Steven J. Isakoff, Erica L. Mayer, Lei He, Tiffany A. Traina, Lisa A. Carey, Karen J. Krag, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Steven E. Come, Kirsten M. Timms, Anne-Renee Hartman, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, Leif W. Ellisen - Journal of Clinical Oncology 2015 cited by 430

  15. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate

    Authors: Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, Charlotte M. Huijts, Flonné Wildes, Santosh Kumar Bharti, Zhe Zhang, Cesar A. Santa‐Maria, Hua‐Ling Tsai, Chi V. Dang, Vered Stearns, Zaver M. Bhujwalla, Saraswati Sukumar - Clinical Cancer Research 2015 cited by 186

  16. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?

    Authors: Mirat Shah, Maria Raquel Nunes, Vered Stearns - 2018 cited by 132

  17. Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

    Authors: Julia A. Beaver, Danijela Jelovac, Balukrishna Sasidharan, Rory L. Cochran, Sarah Croessmann, Daniel J. Zabransky, Hong Yuen Wong, Patricia Valda Toro, Justin Cidado, Brian Blair, David Chu, Timothy F. Burns, Michaela J. Higgins, Vered Stearns, Lisa K. Jacobs, Mehran Habibi, Julie R. Lange, Paula J. Hurley, Josh Lauring, Dustin A. VanDenBerg, Jill Kessler, Stacie C. Jeter, Michael L. Samuels, Dianna Maar, Leslie Cope, Ashley Cimino‐Mathews, Pedram Argani, Antonio C. Wolff, Ben Ho Park - Clinical Cancer Research 2014 cited by 396

  18. ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

    Authors: Shani Paluch–Shimon, Fátima Cardoso, Ann H. Partridge, Omalkhair Abulkhair, Hatem A. Azim, G. Bianchi-Micheli, Maria João Cardoso, Giuseppe Curigliano, Karen A. Gelmon, Nadia Harbeck, J. Merschdorf, Philip Poortmans, Giancarlo Pruneri, Elżbieta Senkus, Tanja Španić, Vered Stearns, Yvonne Wengström, Fedro A. Peccatori, Olivia Pagani - Annals of Oncology 2020 cited by 253

  19. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    Authors: Harold J. Burstein, Sarah Temin, Holly Anderson, Thomas A. Buchholz, Nancy E. Davidson, Karen Gelmon, Sharon H. Giordano, Clifford A. Hudis, Diana Rowden, Alexander J. Solky, Vered Stearns, Eric P. Winer, Jennifer J. Griggs - Journal of Clinical Oncology 2014 cited by 793

  20. Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

    Authors: N. Lynn Henry, Faouzi Azzouz, Zereunesay Desta, Lang Li, Anne Nguyen, Suzanne Lemler, Jill A. Hayden, Karineh Tarpinian, Elizabeth Yakim, David A. Flockhart, Vered Stearns, Daniel F. Hayes, Anna Maria Storniolo - Journal of Clinical Oncology 2012 cited by 389

  21. Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

    Authors: Vered Stearns - JNCI Journal of the National Cancer Institute 2003 cited by 849

  22. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

    Authors: Harold J. Burstein, Christina Lacchetti, Holly Anderson, Thomas A. Buchholz, Nancy E. Davidson, Karen Gelmon, Sharon H. Giordano, Clifford A. Hudis, Alexander J. Solky, Vered Stearns, Eric P. Winer, Jennifer J. Griggs - Journal of Clinical Oncology 2016 cited by 303

  23. Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer

    Authors: Haoyang Mi, Chang Gong, Jeremias Sulam, Elana J. Fertig, Alexander S. Szalay, Elizabeth M. Jaffee, Vered Stearns, Leisha A. Emens, Ashley Cimino‐Mathews, Aleksander S. Popel - Frontiers in Physiology 2020 cited by 79

  24. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors

    Authors: Hanwen Wang, Richard J. Sové, Mohammad Jafarnejad, Sondra Rahmeh, Elizabeth M. Jaffee, Vered Stearns, Evanthia T. Roussos Torres, Roisín M. Connolly, Aleksander S. Popel - Frontiers in Bioengineering and Biotechnology 2020 cited by 51